Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

Clinical Cancer Research
Mehrotra S, Gopalakrishnan M, Gobburu J, Ji J, Greer JM, Piekarz R, Karp JE, Pratz KW, Rudek MA
November 1, 2017
Learn More LinkedIn Twitter Facebook Email